Facebook | Icon Twitter | Icon Google Plus | IconBlog | Icon

Follow us


1-877-949-5325 9195 Sunset Drive Suite 110
Miami, Florida. 33173

How Immunotherapy Works for Prostate Cancer

An estimated one in seven men will develop prostate cancer in their lifetime. It’s the second most common cancer in men, usually developing after age 50, with the average age being 66. Prostate cancer is treatable, having the best results when it’s detected early in the first stages. There are several clinical trials experimenting with new immunotherapies for prostate cancer treatment.

Prostate cancer

Targeting Cancer Cells

Immunotherapy helps the body’s immune system target and eliminate cancer cells. Certain types of cancer that have shown resistance to chemotherapy and radiation have responded to immunotherapy treatments. When indicated, radiation and/or chemotherapy are used in tandem with immunotherapy. Many of these prostate cancer treatments have some side effects, including urinary incontinence, erectile disfunction, urinary frequency or burning, sexual impotence, and others. Another treatment for prostate cancer, with fewer side effects, is an advanced technology called HIFU.

Cancer Treatment Options

Depending on how far the cancer has spread, or if it has metastasized to other tissues or organs, different prostate cancer treatment options can be used. High-intensity focused ultrasound (HIFU) is a relatively new technique that has been approved for use in the United States since October 2015. The Prostate Cancer Institute specializes in HIFU, using the most recent innovative technologies from Sonacare Medical. The Sonacare’s Sonablate HIFU prostate cancer treatment uses the latest technological advances to this system. Real-time imaging of the prostate allow precise treatment to eliminate only the cancerous cells. There is no damage to surrounding healthy tissue. The Sonacare’s Sonablate HIFU can be repeated if necessary in the same or different areas. Dr. George Suarez, of Sonacare Medical, has performed more HIFU procedures for prostate cancer than any other doctor worldwide.

Development of HIFU

Dr. Suarez designed and developed the first HIFU system, and is fully credentialed in Sonacare’s Sonablate and in EDAP’s HIFU devices. He states that a critical feature of image-guided surgery (HIFU) is how it localizes and verifies ablation of the target in real-time, combining operations into one platform. Integrated imaging, precision ablation, and real-time tissue change validation no longer take three individual procedures. Having HIFU doesn’t preclude the patient from considering other treatment options, such as surgery, radiation, cryosurgery, and others. Sonacare’s Sonablate HIFU is non-invasive, with fewer complications in post-surgery.